Asset profile
Atirmociclib
Small molecule
Evidence outlook · registrational
HR+/HER2- Metastatic Breast Cancer: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2029-01-02.
NCT06465368: The study randomized 121 participants to PF-07220060 plus letrozole or letrozole alone, but it was open-label, with only the biopsy assessment performed centrally in a blinded manner. Its primary endpoint was a Ki-67-based biomarker rather than a clinical outcome, and although the reported percentages favored the combination, statistical significance for the primary comparison was not stated.
Also in development:Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
119 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 82 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Atirmociclib: this drug | Phase 3 | Small molecule | CDK4 | ||
| BGB-43395 | Phase 3 | Small molecule | CDK4 | ||
| HRS-6209 | Phase 2 | Small molecule | CDK4 | ||
| SHR-6209 | Phase 2 | Small molecule | CDK4 | ||
| AVZO-023 | Phase 1/2 | Small molecule | CDK4 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor |
…and 104 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
February 2027 (1)
What to watch
April 2027 (1)
What to watch
August 2027 (1)
What to watch
2029 (2)
2030 (1)
September 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.